航天智造(300446.SZ):關聯方中標控股子公司項目
格隆匯6月24日丨航天智造(300446.SZ)公佈,控股子公司樂凱化學材料有限公司(簡稱“樂凱化學”)在“樂凱化學材料有限公司樂凱新型橡塑助劑產業化基地項目二期3-4#產線工程項目”(簡稱“化學二期項目”)建設過程中,通過公開招標方式選擇項目的設計施工總承包單位,公司關聯方河北樂凱化工工程設計有限公司(簡稱“樂凱工程設計”)作爲項目聯合體牽頭人中標,從而形成關聯交易。
樂凱化學近期通過公開招標方式,選擇“化學二期項目”的設計施工總承包單位。在履行相關法定程序和公示後,確定樂凱工程設計(聯合體牽頭人)、中國建築第六工程局有限公司(聯合體成員)爲中標單位,中標價格爲5,893萬元(其中設計費195萬元,建築安裝工程費3998萬元,設備採購暫估1700萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.